Google+ Facebook Twitter Twitter

Precision genomics in cancer treatments

Scientists have identified genomic signatures in women developing the most common type of breast cancer that can be associated with long-term survival.

A team from NUI Galway analysed the genomes of breast cancer patients to look for associations with survival rates using advanced statistical techniques.

Early detection by national screening programmes and timely treatment for patients diagnosed with “luminal” types of breast cancer have resulted in excellent prognoses, with survival rates of over 80% within five years of treatment.

The challenge of long-term survival, however, is not as well understood and studies have shown that more than half of all recurrences for luminal breast cancers take place after this time point.

The team calculated the level of genome instability across 2000 patients, then used statistical modelling to identify distinct long-term survival outcomes. This enabled them to confirm the significantly worse prognoses for luminal A patients suffering from the most extreme levels of genome instability in their tumour biopsies.

Image Credit | iStock

Related Articles

Diagnose crohn’s with an engineered organism

Researchers have engineered a bacterium with the necessary capabilities for diagnosing a human disease.

Genomic medicine: Coming to the clinic near you?

Dr Rameen Shakur takes a look at how biomedical science and genomics are playing a part in real-world clinical cardiology.

Unintended consequences

Computational biologist Gregorio Alanis- Lobato highlights the need for greater awareness of and further research into the effects of CRISPR-Cas9 genome editing.

The evolution of quality assessment

In 2011, UK NEQAS Cellular Pathology Technique (CPT) carried out tests across four schemes – it now covers 12 schemes with two in the pipeline. We hear from Chantell Hodgson, UK NEQAS CPT Scheme Manager.